What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Enzyme
His primary areas of investigation include Surgery, Anticoagulant, Anesthesia, Internal medicine and Heparin.
His Surgery research incorporates themes from Aspirin and Clinical trial.
His Anticoagulant study combines topics in areas such as Fibrinolytic agent, Warfarin and Intensive care medicine.
His biological study spans a wide range of topics, including Phases of clinical research, Randomized controlled trial, Dabigatran, Edoxaban and Hemostasis.
His research integrates issues of Endocrinology and Cardiology in his study of Internal medicine.
His Heparin research integrates issues from Discovery and development of direct thrombin inhibitors, Thrombin, Pharmacology and Fondaparinux.
His most cited work include:
- Edoxaban versus warfarin in patients with atrial fibrillation (2856 citations)
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials (2576 citations)
- Oral Apixaban for the Treatment of Acute Venous Thromboembolism (1398 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Anticoagulant, Heparin, Intensive care medicine and Thrombosis.
His research in Internal medicine tackles topics such as Cardiology which are related to areas like Aspirin.
He usually deals with Anticoagulant and limits it to topics linked to Anesthesia and Partial thromboplastin time.
In his study, Fibrin, Pharmacology, Biochemistry and Coagulation is strongly linked to Thrombin, which falls under the umbrella field of Heparin.
His Intensive care medicine research is multidisciplinary, relying on both Venous thromboembolism, Clinical trial, Warfarin and Antithrombotic.
Surgery covers Jeffrey I. Weitz research in Thrombosis.
He most often published in these fields:
- Internal medicine (29.34%)
- Anticoagulant (21.03%)
- Heparin (20.85%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (29.34%)
- Thrombosis (20.11%)
- Rivaroxaban (13.84%)
In recent papers he was focusing on the following fields of study:
Jeffrey I. Weitz mainly investigates Internal medicine, Thrombosis, Rivaroxaban, Venous thromboembolism and Intensive care medicine.
His work in Internal medicine addresses subjects such as Cardiology, which are connected to disciplines such as Factor Xa Inhibitor.
Jeffrey I. Weitz has researched Thrombosis in several fields, including Anticoagulant, Emergency medicine, Heparin and Dosing.
His work deals with themes such as Dabigatran, Aspirin and Randomized controlled trial, which intersect with Rivaroxaban.
His studies in Apixaban integrate themes in fields like Hemostasis, Anesthesia and Venography.
To a larger extent, Jeffrey I. Weitz studies Warfarin with the aim of understanding Edoxaban.
Between 2017 and 2021, his most popular works were:
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up (1132 citations)
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (114 citations)
- Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. (90 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Enzyme
- Gene
His scientific interests lie mostly in Internal medicine, Thrombosis, Stroke, Randomized controlled trial and Intensive care medicine.
As part of his studies on Internal medicine, Jeffrey I. Weitz often connects relevant areas like Cardiology.
His Thrombosis study incorporates themes from Factor XIa and Side effect.
His study focuses on the intersection of Intensive care medicine and fields such as Antithrombotic with connections in the field of Disease, Dosing, Review article, Heparin and Coagulation system.
His Rivaroxaban study combines topics from a wide range of disciplines, such as Dabigatran, Placebo and Vitamin K antagonist.
His research investigates the connection between Apixaban and topics such as Anesthesia that intersect with problems in TIMI.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
